SOHO 2021 | Future directions in MDS
Andrew Brunner
• 13 Sep 2021
Andrew Brunner, MD, of Massachusetts General Hospital, Boston, MA, briefly describes our current knowledge of myelodysplastic syndromes (MDS). Improved understanding of clonal hematopoiesis, the process in which hematopoietic stem cells differentiate into genetically distinct subpopulations of blood cells, as well as the molecular heterogeneity of MDS will aid the development of an enhanced treatment pathway for patients. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
